C. Liang

发表

Protein kinase inhibitors: structural determinants for target specificity.

G. Mcmahon, L. Sun, C. Liang, 1998, Current opinion in drug discovery & development.

Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)

H. Wakelee, C. Liang, C. Lovly, 2016 .

Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)

J. Neal, H. Wakelee, C. Liang, 2016 .

Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.

G. Mcmahon, L. Sun, C. Tang, 1999, Journal of medicinal chemistry.

Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.

C. Liang, Ling-hua Meng, Jian Ding, 2012, Biochemical pharmacology.

Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.

H. Wakelee, J. Nieva, T. Shaffer, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

C. Liang, E. Chan, J. Picus, 2021, Investigational New Drugs.

A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.

W. Pao, H. Wakelee, C. Liang, 2014 .

Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling

A. Angelucci, C. Liang, G. Gravina, 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial

C. Liang, X. Ren, Lin Yang, 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.

S. Hubbard, G. Mcmahon, L. Sun, 2000, Journal of medicinal chemistry.

New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK

M. Cilli, C. Liang, J. Gibbons, 2015, Oncotarget.

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Roman K. Thomas, W. Pao, C. Liang, 2011, Cancer research.

Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

C. Liang, J. Bendell, H. Arkenau, 2018, The oncologist.

Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment

David Camacho Trujillo, F. Speleman, O. Delattre, 2015, Clinical Cancer Research.

A novel lead compound CM-118

C. Liang, Hui Zhao, Ker Yu, 2014, Cancer biology & therapy.

Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors

E. Stanchina, Roman K. Thomas, W. Pao, 2011 .

Simultaneous targeting of PI3Kδ and a PI3Kδ-dependent MEK1/2-Erk1/2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia

Weiliang Zhu, L. Ding, C. Liang, 2014, Oncotarget.

Simultaneous targeting of PI 3 Kδ and a PI 3 Kδ-dependent MEK 1 / 2-Erk 1 / 2 pathway for therapy in pediatric B-cell acute lymphoblastic leukemia

Weiliang Zhu, L. Ding, C. Liang, 2014 .

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

C. Liang, J. Cherrington, S. Vasile, 2006, Molecular Cancer Therapeutics.

SU 14813 : a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

C. Liang, J. Cherrington, S. Vasile, 2006 .

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.

L. Ellis, C. Liang, J. Cherrington, 2000, Anti-cancer drug design.

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

F. Gao, C. Liang, L. Ratner, 2022, Cancer Chemotherapy and Pharmacology.

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Ying Cheng, H. Wakelee, T. Mok, 2021, JAMA oncology.

Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.

S. Honsawek, G. Mcmahon, L. Sun, 2001, Cancer research.

Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.

Hui Chen, Chris Liang, C. Liang, 2003, Journal of medicinal chemistry.

Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

J. Neal, H. Wakelee, C. Liang, 2018, Clinical Cancer Research.

Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel

R. Jeraj, J. Kolesar, C. Liang, 2018, Cancer Chemotherapy and Pharmacology.

Design and synthesis of aminopropyl tetrahydroindole-based indolin-2-ones as selective and potent inhibitors of Src and Yes tyrosine kinase.

Robert A Blake, Chris Liang, C. Liang, 2004, Bioorganic & medicinal chemistry letters.

OA03.08 Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI): Topic: Medical Oncology

H. Wakelee, C. Liang, L. Gandhi, 2017 .

ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3

Ying Cheng, H. Wakelee, T. Mok, 2020 .

A Phase 1 Trial of X-396, a Novel ALK Inhibitor, in Patients With Advanced Solid Tumors

H. Wakelee, C. Liang, C. Lovly, 2014 .

P1.14-32 Rash and Efficacy in Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer Patients Treated with Ensartinib

J. Neal, H. Wakelee, C. Liang, 2019, Journal of Thoracic Oncology.

Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity

C. Liang, Yang Wang, Xiaobin Yuan, 2022, Molecular therapy oncolytics.

Phase I, first-in-human trial of an oral VEGFR tyrosine kinase inhibitor (TKI) x-82 in patients (pts) with advanced solid tumors.

Suzanne F. Jones, C. Liang, J. Bendell, 2012 .

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study

C. Liang, Kun Liu, Xiaoxin Li, 2023, Eye.

Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study

P. Rosenfeld, J. Slakter, M. Elman, 2017, JAMA ophthalmology.

MA 07.02 Response to Ensartinib in TKI Naïve ALK+ NSCLC Patients

J. Neal, H. Wakelee, J. Nieva, 2017 .

P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC: Topic: ALK

J. Neal, H. Wakelee, C. Liang, 2016 .

Colon Carcinoma Cells A Novel cdk 2-selective Inhibitor , SU 9516 , Induces Apoptosis in Updated

G. Mcmahon, C. Liang, S. Wadler, 2001 .

A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.

G. Mcmahon, L. Sun, C. Liang, 2001, Cancer research.

Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).

J. Neal, H. Wakelee, C. Liang, 2016 .

Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.

C. Liang, Ling-hua Meng, Jian Ding, 2012, Biochemical pharmacology.